loader
Please Wait
Applying Filters...
menu
    • menu

    Digital Content for Lasmiditan

    Client Email Product
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    Menu

    Lasmiditan

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PRICE INFORMATION

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 3,857Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    FDA Confirms Para IV Patent Litigation for Lasmiditan Succinate (Reyvow) Tablets
    FDA Confirms Para IV Patent Litigation for Lasmiditan Succinate (Reyvow) Tablets

    26 Mar 2024

    // FDA

    https://www.pharmacompass.com/pdf/news/fda-confirms-para-iv-patent-litigation-for-lasmiditan-succinate-reyvowtablets-11947.pdf

    FDA
    26 Mar 2024
    Share Share
    Eli Lilly's Rayvow (lasmiditan) Receives Approval in Europe
    Eli Lilly's Rayvow (lasmiditan) Receives Approval in Europe

    03 Oct 2022

    // EMA

    https://www.pharmacompass.com/pdf/news/eli-lillys-rayvow-lasmiditan-receives-approval-in-europe-9507.pdf

    EMA
    03 Oct 2022
    Share Share
    Eli Lilly, Daiichi Sankyo partner to commercialize lasmiditan succinate in Japan
    Eli Lilly, Daiichi Sankyo partner to commercialize lasmiditan succinate in Japan

    31 Aug 2021

    // PHARMABIZ

    http://www.pharmabiz.com/NewsDetails.aspx?aid=142206&sid=2

    PHARMABIZ
    31 Aug 2021
    Share Share
    REYVOW® Positive Data in New Phase 3 Consistency of Effect Study
    REYVOW® Positive Data in New Phase 3 Consistency of Effect Study

    06 Oct 2020

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/reyvow-lasmiditan-c-v-demonstrated-superior-pain-freedom-at-2-hours-in-at-least-2-of-3-migraine-attacks-in-new-phase-3-consistency-of-effect-study-301145956.html

    PRNEWSWIRE
    06 Oct 2020
    Share Share
    Eli Lilly's Reyvow, squaring off against AbbVie and Biohaven
    Eli Lilly's Reyvow, squaring off against AbbVie and Biohaven

    11 Sep 2020

    // Eric Sagonowsky FIERCE PHARMA

    https://www.fiercepharma.com/pharma/eli-lilly-squaring-off-against-abbvie-and-biohaven-touts-data-showing-early-and-lasting

    Eric Sagonowsky FIERCE PHARMA
    11 Sep 2020
    Share Share
    Lilly's migraine med lasmiditan successful in another late-stage study
    Lilly's migraine med lasmiditan successful in another late-stage study

    10 Sep 2020

    // SEEKINGALPHA

    https://seekingalpha.com/news/3613241-lillys-migraine-med-lasmiditan-successful-in-another-late-stage-study

    SEEKINGALPHA
    10 Sep 2020
    Share Share